Picture of Regen BioPharma logo

RGBP Regen BioPharma Income Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapSucker Stock

Annual income statement for Regen BioPharma, fiscal year end - September 30th, USD millions except per share, conversion factor applied.

2019
September 30th
2020
September 30th
2021
September 30th
2022
September 30th
2023
September 30th
Period Length:12 M12 M12 M12 M12 M
Source:10-K10-K10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Revenue
Total Revenue0.110.110.1710.2360.237
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses0.8060.3191.150.670.922
Operating Profit-0.696-0.209-0.976-0.435-0.686
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes-2.623.41-6.772.441.16
Net Income After Taxes-2.623.41-6.772.441.16
Minority Interest
Net Income Before Extraordinary Items
Net Income-2.623.41-6.772.441.16
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income-2.622.73-6.772.441.02
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS-1.932.89-2.970.8050.289